Invesco WilderHill Clean Energy ETF vs Repligen Corporation Common Stock — how do they compare? Invesco WilderHill Clean Energy ETF trades at $25.75 (market cap $315.85M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 35.3× Invesco WilderHill Clean Energy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco WilderHill Clean Energy ETF for 47 Days and Repligen Corporation Common Stock for 0 Days on average.
| PBW | RGEN | |
|---|---|---|
Market Cap | $315.85M | $11.14B |
Volume | 452,833 | 1,259,263 |
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $194.57 |
52-Week Low | $25.77 | $102.87 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | — | $11.02B |
Signals from Pluang's Aura AI — not financial advice
The Invesco WilderHill Clean Energy ETF (PBW) trades at $27.33, down 0.33% on the day, with a bearish technical signal driven by moving averages. Key financial ratios such as P/E and P/S are not applicable for this ETF. Recent news highlights institutional selling, with IFP Advisors cutting its stake by 96.3% in Q2 2026 (SEC filing, September 18, 2026).
The outlook is cautious due to technical weakness and institutional outflows. Opportunities lie in the clean energy theme amid global investment, but risks include high volatility and concentrated portfolio strategy. The ETF's performance is tied to sector sentiment rather than traditional corporate fundamentals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →